CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 88 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q3 2020. The put-call ratio across all filers is 0.11 and the average weighting 1.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2021 | $32,919,000 | -10.6% | 278,011 | -10.9% | 0.01% | -11.1% |
Q4 2020 | $36,833,000 | +6.3% | 311,853 | 0.0% | 0.01% | 0.0% |
Q3 2020 | $34,659,000 | -8.0% | 311,853 | -15.4% | 0.01% | -18.2% |
Q2 2020 | $37,684,000 | -7.5% | 368,801 | -2.3% | 0.01% | -26.7% |
Q1 2020 | $40,733,000 | -13.2% | 377,401 | -6.4% | 0.02% | +15.4% |
Q4 2019 | $46,932,000 | +1.7% | 403,263 | 0.0% | 0.01% | -7.1% |
Q3 2019 | $46,162,000 | +20.1% | 403,263 | 0.0% | 0.01% | +16.7% |
Q2 2019 | $38,431,000 | +4.4% | 403,263 | 0.0% | 0.01% | 0.0% |
Q1 2019 | $36,798,000 | +59.4% | 403,263 | +32.6% | 0.01% | +33.3% |
Q4 2018 | $23,082,000 | -5.1% | 304,075 | 0.0% | 0.01% | +12.5% |
Q3 2018 | $24,326,000 | -7.3% | 304,075 | +15.1% | 0.01% | -11.1% |
Q2 2018 | $26,236,000 | +22.6% | 264,131 | 0.0% | 0.01% | +12.5% |
Q1 2018 | $21,395,000 | +2.8% | 264,131 | 0.0% | 0.01% | +14.3% |
Q4 2017 | $20,806,000 | -14.6% | 264,131 | 0.0% | 0.01% | -22.2% |
Q3 2017 | $24,371,000 | – | 264,131 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Maso Capital Partners Ltd | 164,500 | $15,011,000 | 10.32% |
HHLR ADVISORS, LTD. | 2,751,200 | $251,047,000 | 6.99% |
Dalton Investments, Inc. | 113,851 | $10,389,000 | 4.54% |
Point72 Hong Kong Ltd | 115,939 | $10,579,000 | 4.17% |
York Capital Management Global Advisors, LLC | 991,233 | $90,450,000 | 4.05% |
RUDMAN ERROL M | 58,000 | $5,293,000 | 3.57% |
Greenwoods Asset Management Ltd | 479,580 | $43,762,000 | 2.69% |
Parametrica Management Ltd | 3,663 | $334,000 | 0.71% |
Temasek Holdings (Private) Ltd | 990,000 | $90,338,000 | 0.62% |
Athos Capital Ltd | 8,290 | $756,000 | 0.49% |